ArticleCell reports. Medicine2026

DF6215, an α-optimized IL-2-Fc fusion, expands immune effectors and drives robust preclinical anti-tumor activity.

Adam P Stockmann et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.